Novartis pauses autoimmune cell therapy studies after deaths
Novartis reviews safety after three patient deaths linked to severe immune response
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.timeslive.co.za — the content belongs to TimesLIVE.